TY - JOUR
T1 - The spatiotemporal evolution of lymph node spread in early breast cancer
AU - Barry, Peter
AU - Vatsiou, Alexandra
AU - Spiteri, Inmaculada
AU - Nichol, Daniel
AU - Cresswell, George D.
AU - Acar, Ahmet
AU - Trahearn, Nicholas
AU - Hrebien, Sarah
AU - Garcia-Murillas, Isaac
AU - Chkhaidze, Kate
AU - Ermini, Luca
AU - Huntingford, Ian Said
AU - Cottom, Hannah
AU - Zabaglo, Lila
AU - Koelble, Konrad
AU - Khalique, Saira
AU - Rusby, Jennifer E.
AU - Muscara, Francesca
AU - Dowsett, Mitch
AU - Maley, Carlo C.
AU - Natrajan, Rachael
AU - Yuan, Yinyin
AU - Schiavon, Gaia
AU - Turner, Nicholas
AU - Sottoriva, Andrea
N1 - Publisher Copyright:
© 2018 American Association for Cancer Research.
PY - 2018/10/1
Y1 - 2018/10/1
N2 - Purpose: The most significant prognostic factor in early breast cancer is lymph node involvement. This stage between localized and systemic disease is key to understanding breast cancer progression; however, our knowledge of the evolution of lymph node malignant invasion remains limited, as most currently available data are derived from primary tumors. Experimental Design: In 11 patients with treatment-na€ve node-positive early breast cancer without clinical evidence of distant metastasis, we investigated lymph node evolution using spatial multiregion sequencing (n ¼ 78 samples) of primary and lymph node deposits and genomic profiling of matched longitudinal circulating tumor DNA (ctDNA). Results: Linear evolution from primary to lymph node was rare (1/11), whereas the majority of cases displayed either early divergence between primary and nodes (4/11) or no detectable divergence (6/11), where both primary and nodal cells belonged to a single recent expansion of a metastatic clone. Divergence of metastatic subclones was driven in part by APOBEC. Longitudinal ctDNA samples from 2 of 7 subjects with evaluable plasma taken perioperatively reflected the two major evolutionary patterns and demonstrate that private mutations can be detected even from early metastatic nodal deposits. Moreover, node removal resulted in disappearance of private lymph node mutations in ctDNA. Conclusions: This study sheds new light on a crucial evolutionary step in the natural history of breast cancer, demonstrating early establishment of axillary lymph node metastasis in a substantial proportion of patients.
AB - Purpose: The most significant prognostic factor in early breast cancer is lymph node involvement. This stage between localized and systemic disease is key to understanding breast cancer progression; however, our knowledge of the evolution of lymph node malignant invasion remains limited, as most currently available data are derived from primary tumors. Experimental Design: In 11 patients with treatment-na€ve node-positive early breast cancer without clinical evidence of distant metastasis, we investigated lymph node evolution using spatial multiregion sequencing (n ¼ 78 samples) of primary and lymph node deposits and genomic profiling of matched longitudinal circulating tumor DNA (ctDNA). Results: Linear evolution from primary to lymph node was rare (1/11), whereas the majority of cases displayed either early divergence between primary and nodes (4/11) or no detectable divergence (6/11), where both primary and nodal cells belonged to a single recent expansion of a metastatic clone. Divergence of metastatic subclones was driven in part by APOBEC. Longitudinal ctDNA samples from 2 of 7 subjects with evaluable plasma taken perioperatively reflected the two major evolutionary patterns and demonstrate that private mutations can be detected even from early metastatic nodal deposits. Moreover, node removal resulted in disappearance of private lymph node mutations in ctDNA. Conclusions: This study sheds new light on a crucial evolutionary step in the natural history of breast cancer, demonstrating early establishment of axillary lymph node metastasis in a substantial proportion of patients.
UR - http://www.scopus.com/inward/record.url?scp=85054067972&partnerID=8YFLogxK
U2 - 10.1158/1078-0432.CCR-17-3374
DO - 10.1158/1078-0432.CCR-17-3374
M3 - Article
C2 - 29891724
AN - SCOPUS:85054067972
SN - 1078-0432
VL - 24
SP - 4763
EP - 4770
JO - Clinical Cancer Research
JF - Clinical Cancer Research
IS - 19
ER -